AGM
IGMS

Alpine Global Management’s IGM Biosciences IGMS Stock Holding History

Alpine Global Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,383
Closed -$511K – 335
2019
Q4 		$511K Buy
+13,383
New +$336K 0.11% 137

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Alpine Global Management's IGMS Position: Q1 2020 in Review

Alpine Global Management sold out of IGM Biosciences (IGMS) in Q1 2020, closing a stake of 13,383 shares — an estimated $511K sold.

Alpine Global Management first reported a position in IGMS in Q4 2019 and held it in 1 quarter. The position peaked at $511K in Q4 2019. 62 funds tracked by Wall St. Rank hold IGMS as of Q1 2020.

  • Alpine Global Management reported no remaining IGM Biosciences position as of Q1 2020 after selling out during the quarter.
  • Alpine Global Management sold 13,383 IGM Biosciences shares in Q1 2020, an estimated $511K.
  • Alpine Global Management first reported a position in IGM Biosciences in Q4 2019 and held it in 1 quarter.
  • Alpine Global Management's IGM Biosciences position peaked at $511K in Q4 2019.
  • 62 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.